Search
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]
Dasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Articaine
go.drugbank.com/drugs/DB09009ApprovedInvestigationalArticaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Mixtures: SEPTANEST® ADRENALINEE AU 1/100.000SYNB1020
go.drugbank.com/drugs/DB17667InvestigationalIt was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalThe antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[L40298] In September 2022, Skysona was approved by the FDA.[L43247]
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.